Log in  First Connection?
  
EnglishJapaneseFrenchSpanishGerman

Blood CancerArchives

Response-adapted lenalidomide-dexamethasone (LenDex) intensification after CyBorD induction for transplant-eligible multiple myeloma: the PIANO study
Blood Cancer
 1 min.

 Published on 28/07/2026 |  Original article (Full-text)  | Minakata, Daisuke et al. | Blood research. Volume 61(1).

Combination therapy with novel agents is the standard initial treatment for transplant-eligible patients with newly diagnosed multiple myeloma. However, the benefit of additional induction therapy for insufficient response remains unclear. This multicenter prospective study investigated response-adapted...

HTML version PDF version  Print abstract

Asciminib as first-line therapy in chronic myeloid leukemia: a systematic review
Blood Cancer
 1 min.

 Published on 21/07/2026 |  Original article (Full-text)  | Han, Jae Joon et al. | Blood research. Volume 61(1).

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the BCR::ABL1 fusion oncogene. Asciminib, a first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor, represents a novel therapeutic approach distinct from conventional ATP-competitive tyrosine kinase...

HTML version PDF version  Print abstract

Global burden of multiple myeloma(1990-2021) and projections up to 2035: a methodical analysis leveraging the global burden of disease 2021 study and Mendelian randomization
Blood Cancer
 1 min.

 Published on 14/07/2026 |  Original article (Full-text)  | Qu, Run et al. | Journal of the Egyptian National Cancer Institute. Volume 38(1).

Multiple myeloma (MM), being the second-most frequently occurring hematologic malignancy, is comprehensively assessed for its global disease burden and risk factors using the Global Burden of Disease (GBD) database and Mendelian Randomization (MR). Methods: This research utilized data from the GBD 2021...

HTML version PDF version  Print abstract